Pharmacokinetics of pazufloxacin mesylate injections in healthy volunteers

AIM: To study the pharmacokinetic characteristics of pazufloxacin mesylate in healthy volunteers. METHODS: Ten healthy volunteers received a single dose of 300 mg of pazufloxacin mesylate by intravenous injection. The plasma concentrations of pazufloxacin mesylate were determined by HPLC method. RESULTS: The concentration-time curve after administration was best fitted to two-compartments open model. The main pharmacokinetics parameters of pazufloxacin mesylate were as follows: T max, ρ max, T 1/2β, AUC (0-8) were (0.52±0.17) h, (6.63± 1.86) mg/L, (1.90±0.24) h, and (13.42±2.96) h·mg/L, respectively. CONCLUSION: Pharmacokinetic study shows that pazufloxacin mesylate has short half-life and high concentration in plasma. Effective concentration by intravenous injection can be achieved after two or three dose of 300 mg pazufloxacin mesylate per day.